We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · September 06, 2021

Activity of Cabozantinib in Pretreated Patients With mRCC With Sarcomatoid Differentiation

Targeted oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Targeted oncology
Cabozantinib in Pretreated Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Real-World Study
Target Oncol 2021 Aug 02;[EPub Ahead of Print], M Santoni, F Massari, E Grande, G Procopio, MR Matrana, M Rizzo, U De Giorgi, U Basso, M Milella, R Iacovelli, G Aurilio, L Incorvaia, S Buti, O Caffo, G Fornarini, F Carrozza, V Mollica, A Rizzo, F Farag, J Molina-Cerrillo, N Battelli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading